

R₇ is H, alkyl, aryl, alkanoyl, aroyl or alkoxy carbonyl, R_{7a}SO₂-, R_{7b}R_{7c}NSO₂- or R_{7b}R_{7c}NCO-;


R_{7a} and R_{7e} are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroaryl;

R_{7b} and R_{7c}, and R_{7f} and R_{7g}, and R_{7d} are the same or different and are independently selected from H, alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

or R_{7b} and R_{7c} may be taken together with the nitrogen to which they are attached to form a stable 3 to 8 membered heterocyclic ring, which, where applicable, includes 1 to 3 heteroatoms in the ring; or R_{7f} and R_{7g} may be taken together with the nitrogen to which they are attached to form a stable 3 to 8 membered ring, which, where applicable, includes 1 to 3 heteroatoms in the ring.

R₈ is H or lower alkyl;

R₉ and R₁₀ are the same or different and are independently selected from H or alkyl; or where at least one of R₉ and R₁₀ is alkyl, R₉ and R₁₀ may be taken together with the carbon or carbons to which they are attached to form a 3 to 7 membered carbocyclic ring, which may include a spirocyclic ring;

and  represents a single bond or a double bond (which may be cis or trans);

or a pharmaceutically acceptable salt thereof (where R₃ is H), or an ester thereof, or a stereoisomer thereof;

and another therapeutic agent which is a hypolipidemic agent, and/or lipid modulating agent and/or antidiabetic agent and/or cardiovascular agent, cerebrovascular agent, and/or other type of therapeutic agent, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of such combination.

Remarks


Claims 21 to 40, 46, 47 and 48 are present, which claims represent the non-elected claims of the parent application. The remaining claims have been cancelled since they are covered in the parent of the present application.

Claims 21 and 46, each now an independent claim, have been amended to include the definition of the HMG CoA reductase inhibitor compound as defined in Claim 1 as allowed in parent U.S. Application Serial No. 10/007,407.

It is believed that this application is now in good form for examination.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

A handwritten signature in cursive script, appearing to read "Burton Rodney", is written over a horizontal line.


Burton Rodney
Attorney for Applicants
Reg. No. 22,076

Date: *June 24, 2003*


MARKED-UP COPY TO SHOW CHANGES

Please cancel Claims 1 to 20, 41 to 44 and 49.

21. Amended A pharmaceutical combination comprising the HMG CoA reductase inhibitor compound having the structure



wherein X is O, S, SO, SO₂ or NR₇;



n is 0 or 1;

R₁ and R₂ are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R₃ is H or lower alkyl or a metal ion;

R₄ is H, halogen, CF₃, hydroxy, alkyl, alkoxy, carboxyl, carboxyalkyl-, aminoalkyl, amino, alkanoylamino, aroylamino, cyano, alkoxyCON(R_{7d})-, R_{7f}R_{7g}NCO₂-, R_{7f}R_{7g}NCO-, R_{7c}SO₂N(R_{7d})-, R_{7f}R_{7g}NSO₂N(R_{7d})-, R_{7c}OCO₂- or R_{7c}OCO;


R₇ is H, alkyl, aryl, alkanoyl, aroyl or alkoxycarbonyl, R_{7a}SO₂-, R_{7b}R_{7c}NSO₂- or R_{7b}R_{7c}NCO-;

R_{7a} and R_{7c} are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R_{7b} and R_{7e}, and R_{7f} and R_{7g}, and R_{7d} are the same or different and are independently selected from H, alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;


R₈ is H or lower alkyl;

R₉ and R₁₀ are the same or different and are independently selected from H or alkyl; or where at least one of R₉ and R₁₀ is alkyl, R₉ and R₁₀ may be taken together with the carbon or carbons to which they are attached to form a 3 to 7 membered carbocyclic ring, which may include a spirocyclic ring;


and  represents a single bond or a double bond (which may be cis or trans);

or a pharmaceutically acceptable salt thereof (where R₃ is H), or an ester thereof, or a stereoisomer thereof [as defined in Claim 1] and another therapeutic agent which is one or more hypolipidemic agents or lipid-lowering agents, or lipid agents, or lipid modulating agents, and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet aggregation inhibitors, anti-dementia agents, anti-Alzheimer's agents, anti-osteoporosis agents, and/or hormone replacement therapeutic agents, and/or other cardiovascular agents (including anti-anginal agents, anti-arrhythmic agents, anti-atherosclerosis agents, anti-inflammatory agents, anti-arthritis agents, anti-platelet agents, anti-heart failure agents), anti-cancer agents, anti-infective agents, hormone replacement agents, growth hormone secretagogues, selective androgen receptor modulators, and/or immunomodulatory agents.

46. Amended A method for treating cholesterol related diseases, diabetes and related diseases, cardiovascular diseases, cerebrovascular diseases, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a combination of a compound having the structure



wherein X is O, S, SO, SO₂ or NR₇;



n is 0 or 1;

R_1 and R_2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R_3 is H or lower alkyl or a metal ion;

R_4 is H, halogen, CF_3 , hydroxy, alkyl, alkoxy, carboxyl, carboxyalkyl-, aminoalkyl, amino, alkanoylamino, aroylamino, cyano, alkoxyCON(R_{7d})-, $R_{7f}R_{7g}NCO_2$ -, $R_{7f}R_{7g}NCO$ -, $R_{7e}SO_2N(R_{7d})$ -, $R_{7f}R_{7g}NSO_2N(R_{7d})$ -, $R_{7e}OCO_2$ - or $R_{7e}OCO$;

R_7 is H, alkyl, aryl, alkanoyl, aroyl or alkoxycarbonyl, $R_{7a}SO_2$ -, $R_{7b}R_{7c}NSO_2$ - or $R_{7b}R_{7c}NCO$ -;


R_{7a} and R_{7c} are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroaryl;

R_{7b} and R_{7c} , and R_{7f} and R_{7g} , and R_{7d} are the same or different and are independently selected from H, alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

or R_{7b} and R_{7c} may be taken together with the nitrogen to which they are attached to form a stable 3 to 8 membered heterocyclic ring, which, where applicable, includes 1 to 3 heteroatoms in the ring; or R_{7f} and R_{7g} may be taken together with the nitrogen to which they are attached to form a stable 3 to 8 membered ring, which, where applicable, includes 1 to 3 heteroatoms in the ring.

R_8 is H or lower alkyl;

R_9 and R_{10} are the same or different and are independently selected from H or alkyl; or where at least one of R_9 and R_{10} is alkyl, R_9 and R_{10} may be taken together with the carbon or carbons to which they are attached to form a 3 to 7 membered carbocyclic ring, which may include a spirocyclic ring;

and  represents a single bond or a double bond (which may be cis or trans);

or a pharmaceutically acceptable salt thereof (where R_3 is H), or an ester thereof, or a stereoisomer thereof [as defined in Claim 1] and another therapeutic agent which is a hypolipidemic agent, and/or lipid modulating agent and/or antidiabetic agent and/or cardiovascular agent, cerebrovascular agent, and/or other type of therapeutic agent, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of such combination.